Teleman Dan Benjamin 4

What Happened
Teleman Dan Benjamin, CEO of Nasus Pharma Ltd (NSRX), reported a purchase of 15,000 common shares on 2026-03-31 at $2.04 per share, for a total cash outlay of $30,600. This was reported on a Form 4 filed 2026-04-01. A direct purchase by a company insider is a straightforward acquisition (Form 4 code "P") rather than a sale.

Key Details

• Transaction date and price: 2026-03-31 — 15,000 shares @ $2.04 each. Total value: $30,600.
• Transaction type: Purchase (Form 4 code "P"); listed as open-market or private purchase on the filing.
• Shares owned after transaction: Not specified in the data provided in this summary (see the full Form 4 for total holdings).
• Footnotes/plan: No 10b5-1 plan or special footnotes were disclosed in the provided details.
• Timeliness: Form 4 filed 2026-04-01 (timely filing; not marked late).

Context
Insider purchases are often watched by retail investors as a signal that executives are willing to commit personal capital to the company, but they are not proof of future performance. For full context, check the complete Form 4 for total post-transaction holdings and any explanatory footnotes.